SuperworthBeam Therapeutics price to sales ratio BEAM
Market value divided by revenue over the last twelve months, since 2022.
- Today, Oct 23, 2026
- 15.9×
- 5-year median
- 27.5×
- Against its 5-year history
- 23rd
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 4.6× to 84.9×
- Peer median
- 6.8×
Beam Therapeutics' price to sales ratio is 15.9× as of Oct 23, 2026.
That is below its 5-year median of 27.5×, lower than on 77% of days in the last 5 years.
Over that time it ranged from 4.6× in Apr 2024 to 84.9× in Mar 2022.
The median for 10 biotech stocks of a similar size is 6.8×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 15.9× | 15.5× | 57.5× |
| 2025 | 51.0× | 5.6× | 51.0× |
| 2024 | 6.3× | 4.6× | 34.0× |
| 2023 | 27.2× | 17.5× | 46.5× |
| 2022 | 30.0× | 30.0× | 84.9× |
Against its peers
Companies in Biotechnology nearest Beam Therapeutics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| BEAMBeam Therapeutics | 15.9× |
| ADMAAdma Biologics | 4.7× |
| VCELVericel | 7.1× |
| MGTXMeiraGTx | 2.2× |
| KRYSKrystal Biotech | 20.9× |
| RGENRepligen | 12.7× |
| TECHBIO-TECHNE | 9.4× |
| HALOHalozyme Therapeutics | 8.6× |
| NBIXNeurocrine Biosciences | 4.3× |
| EXELExelixis | 6.6× |
| INCYIncyte | 4.0× |
| Peer median | 6.8× |
Where Beam Therapeutics ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Beam Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.